Axa
SUPN icon

Axa’s Supernus Pharmaceuticals SUPN Stock Holding History

Axa’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,452
Closed -$424K – 898
2025
Q2 		$424K Buy
+13,452
New +$431K ﹤0.01% 1004
2021
Q1 		– Sell
-8,900
Closed -$224K – 1329
2020
Q4 		$224K Buy
+8,900
New +$192K ﹤0.01% 1164
2019
Q4 		– Sell
-188,446
Closed -$5.18M – 1308
2019
Q3 		$5.18M Sell
188,446
-6,767
-3% -$201K 0.02% 641
2019
Q2 		$6.46M Buy
195,213
+14,835
+8% +$508K 0.03% 576
2019
Q1 		$6.32M Buy
180,378
+31,255
+21% +$1.16M 0.02% 575
2018
Q4 		$4.95M Buy
149,123
+22,604
+18% +$972K 0.02% 607
2018
Q3 		$6.37M Buy
126,519
+124
+0.1% +$6.12K 0.02% 605
2018
Q2 		$7.57M Sell
126,395
-60,056
-32% -$3.11M 0.03% 535
2018
Q1 		$8.54M Sell
186,451
-2,597
-1% -$108K 0.03% 496
2017
Q4 		$7.53M Hold
189,048
– – 0.03% 556
2017
Q3 		$7.56M Sell
189,048
-25,621
-12% -$1.11M 0.03% 519
2017
Q2 		$9.25M Buy
214,669
+6,399
+3% +$228K 0.04% 440
2017
Q1 		$6.52M Buy
+208,270
New +$5.58M 0.03% 542
2016
Q1 		– Sell
-30,500
Closed -$410K – 1408
2015
Q4 		$410K Buy
+30,500
New +$472K ﹤0.01% 1065

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa's SUPN Position: Q3 2025 in Review

Axa sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 13,452 shares — an estimated $424K sold.

Axa first reported a position in SUPN in Q4 2015 and held it in 14 quarters. The position peaked at $9.25M in Q2 2017. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Axa reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Axa sold 13,452 Supernus Pharmaceuticals shares in Q3 2025, an estimated $424K.
  • Axa first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 14 quarters.
  • Axa's Supernus Pharmaceuticals position peaked at $9.25M in Q2 2017.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.